MULTIPLE MYELOMA COMPREHENSIVE PROFILE Test
Test Name: MULTIPLE MYELOMA COMPREHENSIVE PROFILE Test
Components:
- CBC
- Urea
- Creatinine
- Calcium, total
- Albumin
- LDH
- Beta 2 Microglobulin
- Protein electrophoresis, serum
- Immunotyping, serum
- Kappa / Lambda Light Chains Free, serum
- Immunoglobulin Profile, serum
- MRD for Multiple Myeloma
Price: 3510.0 AED
Sample Condition: 5 mL (3 mL min.) serum from 1 SST AND 3 mL (2 mL min.) whole blood in 1 Lavender Top (EDTA) tube. Ship refrigerated. Overnight fasting is preferred AND 3 mL (1 mL min.) Bone Marrow (first pull aspirate) in 1 Green Top (Sodium Heparin) tube AND 1 or 2 unstained Bone marrow smears to be made at source. Mix thoroughly & Ship immediately at 18-22°C or at 4-8°C. DO NOT FREEZE. Following information is mandatory: Sample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical History to include if patient is on anti-CD38 therapy; Original TRF; Date and time when sample was drawn.
Report Delivery: Sample Daily by 9 am; Report 3 Working days
Method: Capillary electrophoresis, Agarose Gel Electrophoresis, Immunoturbidimetry, CLIA Spectrophotometry, Electrical impedance, VCS Nephelometry, Flow cytometry
Test type: Multiple Myeloma
Doctor: Oncologist
Test Department: FLOW CYTOMETRY
Pre Test Information: Overnight fasting preferred. Following information is mandatory: Sample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical History to include if patient is on anti-CD38 therapy; Original TRF; Date and time when sample was drawn.
Test Details
The Multiple Myeloma Comprehensive Profile test is a diagnostic tool used to evaluate and monitor multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. This test provides a comprehensive analysis of various markers and genetic abnormalities associated with multiple myeloma. The test typically includes the following components:
- Complete Blood Count (CBC): This test measures the number of red blood cells, white blood cells, and platelets in the blood. Abnormalities in these cell counts can indicate the presence of multiple myeloma.
- Serum Protein Electrophoresis (SPEP): This test separates proteins in the blood and measures the levels of different types of proteins, including immunoglobulins (IgG, IgA, IgM). Abnormal levels of these proteins can indicate the presence of multiple myeloma.
- Urine Protein Electrophoresis (UPEP): This test evaluates the presence of abnormal proteins in the urine, such as Bence Jones proteins. Bence Jones proteins are often associated with multiple myeloma.
- Serum Free Light Chain Assay: This test measures the levels of free light chains (kappa and lambda) in the blood. Abnormal levels of these light chains can indicate the presence of multiple myeloma.
- Beta-2 Microglobulin: This test measures the levels of beta-2 microglobulin, a protein that is often elevated in multiple myeloma.
- Cytogenetic Analysis: This test examines the genetic abnormalities present in the cancer cells. Common abnormalities in multiple myeloma include translocations involving the immunoglobulin genes.
- Fluorescence In Situ Hybridization (FISH): This test uses fluorescent probes to identify specific genetic abnormalities, such as deletions or translocations, in the cancer cells.
- Bone Marrow Aspiration and Biopsy: This procedure involves extracting a sample of bone marrow for examination under a microscope. It helps determine the percentage of plasma cells present and assess the overall health of the bone marrow.
The Multiple Myeloma Comprehensive Profile test provides valuable information for diagnosing and monitoring multiple myeloma. It helps healthcare professionals develop personalized treatment plans and evaluate the response to therapy.
Test Name | MULTIPLE MYELOMA COMPREHENSIVE PROFILE Test |
---|---|
Components | *CBC*Urea*Creatinine*Calcium, total *Albumin*LDH *Beta 2 Microglobulin *Protein electrophoresis, serum*Immunotyping, serum*Kappa / Lambda Light Chains Free, serum *Immunoglobulin Profile, serum*MRD for Multiple Myeloma |
Price | 3510.0 AED |
Sample Condition | 5 mL (3 mL min.) serum from 1 SST AND 3 mL (2 mL min.) whole blood in 1 Lavender Top (EDTA) tube. Ship refrigerated. Overnight fasting is preferred AND 3 mL (1 mL min.) Bone Marrow (first pull aspirate) in 1 Green Top (Sodium Heparin) tube AND 1 or 2 unstained Bone marrow smears to be made at source. Mix thoroughly & Ship immediately at18-22?\u00f8C or at 4-8?\u00f8C. DO NOT FREEZE. Following information is mandatory:\nSample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical History to include if patient is on anti-CD38 therapy; Original TRF;Date and time when sample was drawn. |
Report Delivery | Sample Daily by 9 am; Report 3 Working days |
Method | Capillary electrophoresis,Agarose Gel Electrophoresis, Immunoturbidimetry,CLIASpectrophotometry, Electrical impedence, VCSNephelometry, Flow cytometry |
Test type | Multiple Myeloma |
Doctor | Oncologist |
Test Department: | FLOW CYTOMETRY |
Pre Test Information | Overnight fasting preferred. Following information is mandatory: Sample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical History to include if patient is on anti-CD38 therapy; Original TRF;Date and time when sample was drawn. |
Test Details |
The Multiple Myeloma Comprehensive Profile test is a diagnostic tool used to evaluate and monitor multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. This test provides a comprehensive analysis of various markers and genetic abnormalities associated with multiple myeloma. The test typically includes the following components: 1. Complete Blood Count (CBC): This test measures the number of red blood cells, white blood cells, and platelets in the blood. Abnormalities in these cell counts can indicate the presence of multiple myeloma. 2. Serum Protein Electrophoresis (SPEP): This test separates proteins in the blood and measures the levels of different types of proteins, including immunoglobulins (IgG, IgA, IgM). Abnormal levels of these proteins can indicate the presence of multiple myeloma. 3. Urine Protein Electrophoresis (UPEP): This test evaluates the presence of abnormal proteins in the urine, such as Bence Jones proteins. Bence Jones proteins are often associated with multiple myeloma. 4. Serum Free Light Chain Assay: This test measures the levels of free light chains (kappa and lambda) in the blood. Abnormal levels of these light chains can indicate the presence of multiple myeloma. 5. Beta-2 Microglobulin: This test measures the levels of beta-2 microglobulin, a protein that is often elevated in multiple myeloma. 6. Cytogenetic Analysis: This test examines the genetic abnormalities present in the cancer cells. Common abnormalities in multiple myeloma include translocations involving the immunoglobulin genes. 7. Fluorescence In Situ Hybridization (FISH): This test uses fluorescent probes to identify specific genetic abnormalities, such as deletions or translocations, in the cancer cells. 8. Bone Marrow Aspiration and Biopsy: This procedure involves extracting a sample of bone marrow for examination under a microscope. It helps determine the percentage of plasma cells present and assess the overall health of the bone marrow. The Multiple Myeloma Comprehensive Profile test provides valuable information for diagnosing and monitoring multiple myeloma. It helps healthcare professionals develop personalized treatment plans and evaluate the response to therapy. |